ערך בספרים למניה: Biofrontera Inc (BFRI)

Biofrontera Inc. revenue is based on the implementation of the Ameluz system within US dermatological practice. The book value per share clearly demonstrates this process, and the parameter has stabilized at 0.42. However, aggressive pressure from large holdings complicates expansion. Currently, the mature business is focusing on expanding insurance coverage for keratosis treatment to strengthen its market position.

For Biofrontera Inc., which is scaling sales of dermatological products across US pharmacy chains, resource capitalization is critical for ensuring operational growth. The historical book value per share reflects the difference between all of the issuer's assets and liabilities divided by the number of shares, demonstrating the actual value of a single unit and the company's level of financial stability in the face of market volatility.